Novartis AG (NOVN) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Novartis AG CHF 119, price CHF 118, upside +1.3%, quality 85 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Novartis AG for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range CHF 57.59 – CHF 131.32 · fair‑value band CHF 86.57 – CHF 151.63 · the CHF 117.60 price screens below the CHF 119.10 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Novartis in your weekly email
Every Wednesday you see whether Novartis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Show more
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Stock analysis
Novartis AG (NOVN) currently trades at CHF 117.60, while our model-based Fair Value estimate is CHF 119.10, implying the stock looks roughly 1.3% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of CHF 155.87 per share, and 12 of the 25 models we run sit above the CHF 117.60 price.
Bear case: the Asset-Based group reads lowest at CHF 16.19, and 13 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: CHF 86.57 (bear) to CHF 151.63 (bull), the price of CHF 117.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 85/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Novartis AG reported revenue of $57.1B in FY2025 versus $44.0B in FY2021, a compound +6.8%/yr. Reported net income was $14.6B in FY2025, compounding −11.6%/yr from FY2021.
Key figures
Market cap CHF 230B · P/E ratio 20.8 · P/S ratio 5.34 · EPS (TTM) CHF 5.65 · Dividend yield 3.1% · Net margin 25.6% · Return on equity 34.9% · Return on assets (EBIT) 10.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 10% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 1%, NOVN screens cheaper than that median.
Fair Value models
Bear CHF 86.57Fair Value CHF 119.10Bull CHF 151.63
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (CHF 1.43 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.73/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+10.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.7%
Start year 2020 (pandemic). Over 10 years: +1.3% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+11.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.2%
Dividend (yield on the price)3.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8% vs 6%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 31%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−0.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −2.7% a year for the price and +1.7% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score85 · Top 25%
Fair Value upside+1% · Above median
Profitability
Return on equity (TTM)35% · Top 25%
Return on assets11% · Top 25%
Net margin (TTM)24% · Top 25%
Operating margin (TTM)30% · Above median
Growth and dividend
Revenue growth−1% · Below median
Dividend yield (TTM)3.1% · Above median
Balance sheet
Debt / equity0.61× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (TTM)20.8× · Cheaper than median
P/B6.05× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Novartis AG Fair Value". https://www.fairvalue-calculator.com/stock/NOVN
Frequently asked questions
Is Novartis AG (NOVN) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of CHF 119.10 versus a price of CHF 117.60, about +1% upside (fairly valued).
What is the fair value of NOVN?
Our model-based fair value for Novartis AG is CHF 119.10 (as of Sep 23, 2026), built from audited fundamentals. The current price: CHF 117.60.
What is the quality score of NOVN?
Novartis AG has a Quality Score of 85/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Novartis AG (NOVN)?
Our model-based price target is the fair value of CHF 119.10 (as of Sep 23, 2026) from 25 valuation models. Cautious scenario CHF 86.57, optimistic scenario CHF 151.63. It is a calculation from audited fundamentals, not an analyst target.
What is the Novartis AG stock forecast for 2026?
Our models put fair value at CHF 119.10, about +1% upside versus a price of CHF 117.60 (fairly valued). Cautious scenario CHF 86.57, optimistic scenario CHF 151.63. The calculation is refreshed regularly with new filings.
What is the revenue of Novartis AG (NOVN)?
Novartis AG reported trailing-twelve-month revenue of about $56.6B (latest available figure, as of Sep 23, 2026).
Does Novartis AG pay a dividend?
Novartis AG currently shows a dividend yield of about 3.15% relative to its recent price (as of Sep 23, 2026).
What growth is priced into Novartis AG (NOVN)?
For today's price to be fair in a discounted-cash-flow model, Novartis AG would have to grow free cash flow by -0.4 % per year for five years (discount rate 7.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.7 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of NOVN use?
Our models discount Novartis AG at 7.4 %: a base by market capitalisation (mega), damped by beta 0.50, country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Novartis AG that is -0.4 % per year a year over ten years, using the same discount rate (7.4 %) and the same formula as our fair value.
How much growth has Novartis AG (NOVN) delivered so far?
Over the past 5 years revenue at Novartis AG grew +2.7 % a year. The price currently implies -0.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Novartis AG (NOVN) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Novartis AG (-0.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Novartis AG (NOVN)?
The free-cash-flow yield on the price is 6.61 %: that much free cash flow Novartis AG produces per unit of market value. When it exceeds the discount rate of our models (7.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Novartis AG (NOVN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Novartis AG it is CHF 119.10 per share (as of Sep 23, 2026), against a price of CHF 117.60. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Novartis AG stock overvalued or undervalued in 2026?
As of Sep 23, 2026, NOVN trades below its calculated fair value: price CHF 117.60, fair value CHF 119.10, a gap of about +1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NOVN?
No. The price is what the market pays today (CHF 117.60); the fair value is what the company's own numbers justify (CHF 119.10). For Novartis AG the two are CHF 1.50 per share apart. That gap is exactly why we show both numbers side by side.
How much is Novartis AG worth?
The market values Novartis AG at about CHF 230B (market capitalisation, as of Sep 23, 2026). Per share that is CHF 117.60; our models calculate a fair value of CHF 119.10 per share.
What do the bullish and bearish scenarios say about NOVN?
Our models span a range for Novartis AG: cautious scenario CHF 86.57, base CHF 119.10, optimistic CHF 151.63 per share (as of Sep 23, 2026, price CHF 117.60). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NOVN?
Novartis AG trades at a price-to-earnings ratio of 20.8 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 119.10 is built from several models across several years. Other multiples: PEG 4.2, P/B 6.1, P/S 4.9, EV/EBITDA 12.9.
What is the PEG ratio of NOVN?
The PEG ratio of Novartis AG is 4.17 (P/E divided by earnings growth, as of Sep 23, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Novartis AG (NOVN)?
Balance-sheet figures for Novartis AG (as of Sep 23, 2026): return on equity 34.9%, debt of 0.61 per unit of equity. They feed the Quality Score of 85/100, which measures business quality independently of the share price.
How far is NOVN from its 52-week high?
Novartis AG trades at CHF 117.60, about 10% below its 52-week high of CHF 131.32 and 24% above the low of CHF 94.64 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 119.10 is for.
Which stocks are comparable to Novartis AG?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Novartis AG stock attractive at the current price?
The data as of Sep 23, 2026: price CHF 117.60, calculated fair value CHF 119.10 (+1%), Quality Score 85/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NOVN calculated?
We run Novartis AG through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 119.10, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Novartis AG currently trades 1 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Novartis AG (NOVN)?
The closing price on Sep 23, 2026 was CHF 117.60. Our model-based fair value is CHF 119.10, about +1% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Novartis AG right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Novartis AG (NOVN) come from?
Earnings per share at Novartis AG grew +4.1 % a year from 2014 to 2025. Broken into its drivers: revenue per share +2.2 %, EBIT margin +4.3 %, tax rate −0.1 %, residual (interest, one-offs) −2.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Novartis AG
How large is the market capitalisation of Novartis AG (NOVN)?
The market capitalisation of Novartis AG is CHF 230B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Novartis AG (NOVN)?
The price-to-sales ratio of Novartis AG is 5.34 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Novartis AG (NOVN)?
Earnings per share at Novartis AG are CHF 5.65 (price ÷ EPS = P/E 20.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Novartis AG (NOVN)?
The dividend yield of Novartis AG is 3.1% (payout 65.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Novartis AG (NOVN)?
The net margin of Novartis AG is 25.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Novartis AG (NOVN)?
The return on equity (ROE) of Novartis AG is 34.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Novartis AG (NOVN)?
On an EBIT basis the return on assets of Novartis AG is 10.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Novartis AG (NOVN)?
The operating margin of Novartis AG is 30.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Novartis AG (NOVN)?
Revenue at Novartis AG is growing −0.7% versus a year earlier (3y avg +9.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Novartis AG (NOVN)?
Earnings per share at Novartis AG are growing −9.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Novartis AG (NOVN) carry?
The net debt of Novartis AG is $25.6B (fiscal year 2025, ≈ 1.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Novartis AG in the live analysis
One click puts Novartis AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 23, 2026